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Abstract 
In mammals, the pregnane X receptor (PXR) is a transcription factor with a key 
role in regulating expression of several genes involved in drug biotransformation.  
PXR is present in fish and some genes known to be under its control can be up-
regulated by mammalian PXR ligands.  Despite this, direct involvement of PXR in 
drug biotransformation in fish has yet to be established.  Here, the full length PXR 
sequence was cloned from carp (Cyprinus carpio) and used in a luciferase 
reporter assay to elucidate its role in xenobiotic metabolism in fish.  A reporter 
assay for human PXR (hPXR) was also established to compare transactivation 
between human and carp (cPXR) isoforms.  Rifampicin activated hPXR as 
expected, but not cPXR.  Conversely, clotrimazole (CTZ) activated both isoforms 
and was more potent on cPXR, with an EC50 within the range of concentrations of 
CTZ measured in the aquatic environment.  Responses to other azoles tested 
were similar between both isoforms.  A range of pharmaceuticals tested either 
failed to activate, or were very weakly active, on the cPXR or hPXR.  Overall, 
these results indicate that the cPXR may differ from the hPXR in its responses 
and/or sensitivity to induction by different environmental chemicals, with 
implications for risk assessment because of species differences. 
Keywords: Pregnane X receptor; Common carp; Human; Transient transactivation 
assay; Pharmaceuticals; Azole fungicides 
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Introduction 
Aquatic species may be exposed to a wide range of xenobiotic compounds 
present in the environment, including human pharmaceuticals and personal care 
products.  As a means to combat these exposures, many species have evolved an 
inducible system for xenobiotic metabolism that comprises of a number of enzymes 
including the cytochrome P450 superfamily (notably members of CYP1, 2, 3 and 4 
subfamilies), conjugation enzymes (e.g. glutathione S transferases, UGTs, 
sulfotransferases), and transporter proteins such as P-glycoprotein and other 
multidrug resistance-associated proteins and organic anion transporter proteins.  The 
ultimate purpose of this system is the detoxification and subsequent excretion of 
xenobiotic compounds from the exposed organism in order to minimise cellular 
toxicity. 
Detoxification systems are conserved in vertebrates, and in mammals the 
pregnane X receptor (PXR; NR1I2) plays a major role.  The PXR is an orphan 
nuclear receptor that has a pivotal role in transcriptional regulation of downstream 
detoxification pathways in humans and other mammalian models.  CYP3A, an 
enzyme transcriptionally regulated by the PXR, is implicated in the metabolism of 
over 60% of pharmaceuticals in humans (Goodwin et al., 2002).  The PXR  has a 
large hydrophobic and flexible ligand binding domain (LBD, Kobayashi et al., 2004) 
and this enables its activation by a range of structurally diverse ligands.  There are, 
however, species differences in the inducible nature of the PXR, even within the 
mammals, and this is likely to extend to other vertebrate groups.  For example, 
whereas rifampicin (RIF) is a powerful activator of PXR in humans and rabbits, it fails 
to activate the rat or mouse PXR.  Similarly, pregnenolone 16α-carbonitrile (PCN) 
activates the PXR in rodents, but shows a much reduced activity on human or rabbit 
PXR (Blumberg et al., 1998; Jones et al., 2000; Lehmann et al., 1998; Savas et al., 
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2000).  The basis for this divergence is thought to be due to differences in the amino 
acid sequences in the ligand binding domain (Kliewer et al., 2002).  As a result this 
variability in detoxification efficiency is likely to be reflected in the ability of different 
species groups to successfully process xenobiotics encountered in the environment. 
The PXR pathway is well studied in mammals, but far less information is available 
on the role of this response pathway in fish.  The PXR is present in some fish species, 
including zebrafish (Danio rerio), pufferfish (Takafugu rubripes), fathead minnow 
(Pimephales promelas) and medaka (Oryzias latipes), and it has been shown to be 
activated by some human receptor ligands (Bainy and Stegeman, 2004; Maglich et 
al., 2003; Milnes et al., 2008; Moore et al., 2000).  The downstream effects of PXR 
activation in fish, however, are not well understood.  We have previously shown that 
expression of a number of biotransformation genes (cyp2k, cyp3a, gsta, gstp, mdr1 
and mrp2) are up-regulated after exposure to RIF in carp primary hepatocytes 
(Corcoran et al., 2012) and exposure of carp to the mammalian PXR-agonist CTZ in 
vivo (Corcoran et al., 2014).  Similarly expression of pxr, cyp3a and mdr1 has been 
shown to be elevated following PCN exposure in zebrafish in vivo (Bresolin et al., 
2005).  It has also been demonstrated that RIF exposure results in increased CYP3A 
enzyme activity in primary hepatocytes from grass carp (Ctenopharyngodon idellus) 
and largemouth bass (Micropterus salmoides), (Li et al., 2008) and in a fathead 
minnow (FHM) cell line (Christen et al., 2010).  However, direct involvement of the 
PXR in this response pathway in fish has yet to be established. 
To better understand the role of the PXR in xenobiotic metabolism in teleosts, 
cDNA incorporating the full-length PXR coding region in carp was isolated, and the 
transactivation function of the PXR determined by establishing a carp PXR (cPXR) 
luciferase reporter assay expressing this receptor in transiently transfected cultured 
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cells.  In vitro nuclear receptor reporter assays have been established for various 
nuclear receptors, including oestrogen, androgen, thyroid and glucocorticoid 
receptors in fish (e.g. Bury et al., 2003; Lange et al., 2012; Oka et al., 2013; Todo et 
al., 1999) and applied to establish the roles of specific nuclear receptors in hormone 
signalling in fish. They have also been used as efficient chemical screening systems.  
Here we established a transactivation assay for the common carp PXR (cPXR) and 
investigated its activation by known mammalian PXR ligands RIF, dexamethasone 
(DEX) and clotrimazole (CTZ) and further compared responses of the cPXR with 
hPXR for a range of azole fungicides and pharmaceuticals present in the aquatic 
environment.  
 
 
Materials and Methods 
Cloning of carp PXR sequence 
Total RNA was isolated from frozen carp liver using Tri-reagent (Chomczynski, 
1993) following the manufacturer’s instructions.  Following DNase treatment with 
RQ1 DNase (Promega, Southampton, UK), cDNA was synthesised from 1µg total 
RNA using random hexamers and MMLV reverse transcriptase (Promega), according 
to the manufacturer’s instructions.  This cDNA was used as template for the 
polymerase chain reaction (PCR) amplification of a partial cPXR sequence using the 
degenerate oligonucleotides 5’-TYTTCAGRMGKGCSATGAAR-3’ and 5’-
CCHGGVYGRTCTGGDGARAA-3’ designed in conserved regions from aligned PXR 
sequences in other, closely related species (zebrafish, grass carp, fathead minnow 
and rainbow trout).  The partial cPXR sequence was amplified using GoTaq DNA 
polymerase (Promega) and the following PCR conditions: 96˚C for 2 min, followed by 
35 cycles of denaturation at 94˚C for 1 min, annealing at 55˚C for 1 min and 
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elongation at 72˚C for 3 min.  A 865bp product was obtained, purified using 
NucleoSpin Extract II columns (Macherey-Nagel, Dϋren, Germany) according to the 
manufacturer’s instructions and sequenced (Eurofins Genomics, Ebersberg, 
Germany).  BLAST searches (National Centre of Biotechnology Information (Altschul 
et al., 1990)) of the obtained sequences confirmed similarity with known PXR 
sequences. 
The full cPXR sequence was obtained by rapid amplification of cDNA ends 
(RACE) using the SMARTer RACE cDNA Amplification Kit (Clontech, Mountain View, 
CA, USA) and gene specific primers Cc_GSP1: 5’-ACT ATG AAA GCT GGA GGA 
TGG GGA CGA G-3’ (antisense), Cc_GSP2: 5’-CTC ACT GCA CAT CAC AAG ACC 
TTC GAC A-3’ (sense) and Cc_GSP3: 5’-CCG CAA CCA GGA AAT AGT AGC ACT 
CAC C-3’ (sense) according to the manufacturer’s instructions.  Both 5’ and 3’ RACE 
products were purified as described previously, sequenced, and characterised using 
BLAST and Clustal W (Altschul et al., 1990; Larkin et al., 2007).  A neighbour-joining 
phylogenetic tree was constructed in MEGA7 (Kumar et al., 2016) using a 1000 
replicate bootstrap analysis. 
 
cPXR expression plasmid 
A full-length cPXR fragment was amplified using the primers 
Cc_PXR_F_K_BamHI: 5’-GCG GAT CCG CCA CCA TGT GCT TGC TTC AGC TCA 
GG-3’ and Cc_PXR_R_EcoRV: 5’-CCG ATA TCG TCC TCG CTG GTT TTG ACT G-
3’ designed at the extreme ends of the obtained 5’- and 3’-RACE sequences, 
incorporating restriction sites (BamHI and EcoRV) as well as the kozac sequence 
(which enhances ribosomal binding at the start codon during transcription) in the 
case of the 5’ primer.  For this, cDNA was reverse transcribed from 1 µg of carp liver 
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total RNA as described above and amplified using the Advantage 2 DNA polymerase 
mix (Clontech) according to the manufacturer’s instructions.  The resulting PCR 
product was purified and sequenced to confirm the full sequence length and sub-
cloned into pGEM-T Easy vector (Promega) following the manufacturer’s 
recommendations.  Plasmid DNA was isolated using the Wizard Plus SV minipreps 
DNA Purification system (Promega) according to manufacturer’s instructions.  Using 
the BamHI and EcoRV sites, the cPXR sequences was subsequently ligated into the 
eukaryotic expression vector pcDNA3.1(+) (Invitrogen) using the correspondent 
restriction enzymes (New England Biolabs, Hitchin, UK) and T4 DNA ligase 
(Promega). 
 
hPXR expression plasmid 
Human PXR (hPXR) clone cDNA was purchased from Promega.  1 ng cDNA was 
served as template to amplify the full hPXR sequence using PrimeStar Max DNA 
polymerase (Takara, Ohtsu, Japan) and the primers hPXR_F_BamHI: 5’-GGA TCC 
GCC ATG ACA GTC ACC AGG ACT C-3’ and hPXR_R_XbaI: 5’-TCT AGA TCA 
GCT ACC TGT GAT ACC GAA CAA-3’.  The following PCR protocol was employed: 
21 cycles of denaturation at 98˚C for 10 seconds, annealing at 60˚C for 5 seconds 
and elongation at 72˚C for 15 seconds.  The purified product was then ligated into the 
eukaryotic expression vector pcDNA3.1(+) (Invitrogen) using the correspondent 
restriction enzymes and T4 DNA ligase (Promega). 
 
Construction of pGL4.24-6xPXRE -reporter plasmid 
A reporter vector was constructed based on several variations of the PXR 
response element (PXRE; Figure 1).  The PXRE occurs either as a direct or everted 
repeat of the consensus motif AGTTCA, spaced by between 3 and 8 nucleotides.  
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The PXRE sequence created here was based on that reported in Xie et al. (2000).  
Initially, two complementary long chain oligos 5’-TGA GAG CTC TGA ACT TCA TCA 
AGG TCA GGG ACT GAA CTT TCC TGA CCT TGG CAC AGT GCC ACC ATG AAC 
TTG CCT GAC CTG CTG CAG TTC AAC AGA GTT CAC TCG AGG GT-3’ and 5’-
ACC CTC GAG TGA ACT CTG TTG AAC TGC AGC AGG TCA GGC AAG TTC ATG 
GTG GCA CTG TGC CAA GGT CAG GAA AGT TCA GTC CCT GAC CTT GAT GAA 
GTT CAG AGC TCT CA-3’ were annealed to create double stranded DNA, 
containing four PXRE motifs.  To maximise reporter efficiency, a further PXRE motif 
was added either side of the previously generated long chain oligo using PCR.   One 
ng of the annealed DNA served as template and was amplified using the primers 
PXRE_KpnI 5’-TGA GGT ACC TGA ACT TTT GAT GGG TCA TGA GAG CTC TGA 
ACT TCA TCA AGG-3’ and PXRE2_HindIII 5’-CCT AAG CTT TGA ACT CGA ATG 
AAC TGC ACC CTC GAG TGA ACT CTG TTG-3’ each containing one restriction 
enzyme site (KpnI and HindIII, respectively) and PrimeStar Max DNA polymerase 
(Takara).   The following PCR conditions were employed: 21 cycles of denaturation 
at 98˚C for 10 seconds, annealing at 60˚C for 5 seconds and elongation at 72˚C for 
30 seconds.  After purification, and using the appropriate restriction enzymes KpnI 
and HindIII, the obtained fragment was subsequently ligated into the 
pGL4.24[luc2P/minP] vector (Promega) which contains the firefly (Photinus pyralis) 
luciferase (luc2P) gene, to create the pGL4.24-6xPXRE reporter construct. 
 
Transactivation assays 
COS-7 cells (ATCC CRL-1651) were cultured in phenol-red free Dulbecco's 
modified Eagle's medium containing 1000 mg/L glucose (Life Technologies Ltd, 
Paisley, UK), supplemented with  2 mM L-glutamine (Life Technologies Ltd) and 10% 
charcoal/dextran treated foetal bovine serum (FBS; Hyclone, South Logan, UT, 
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USA).  The cells were maintained at subconfluent densities and sub-cultured when 
reaching 80% confluency. 
For transfection assays, cells were seeded in 24-well plates at 5x104 cells well-1 in 
phenol-red free DMEM (supplemented with 10% charcoal/dextran-treated foetal 
bovine serum (Hyclone).  After 24 h, the cells were transiently transfected with 200 
ng of either pcDNA3.1(+)/cPXR or pcDNA3.1(+)/hPXR, 400 ng of reporter construct 
(either MMTV/luc2/pGL4 (Promega) or pGL4.24-6xPXRE) and 100 ng of pRL-TK 
(driving the Renilla reniformis luciferase gene as an internal control to normalise for 
variations in transfection efficiency) using Fugene HD transfection reagent (Promega) 
in serum-free medium according to the manufacturer’s protocol.  Four hours after 
transfection, cells were treated with PXR agonists (see below).  Forty-eight hours 
after transfection, cells were lysed and the luciferase activities of the cells were 
measured by a chemiluminescence assay with Dual-Luciferase Reporter Assay 
System (Promega) according to the manufacturer’s instructions.  Luminescence was 
measured using an Infinite 200 Pro plate reader (Tecan, Grödig, Austria).  Promoter 
activity was calculated as firefly (Photinus pyralis)-luciferase activity/sea pansy (R. 
reniformis)-luciferase activity. All transfections were done at least three times, 
employing triplicate sample points in each experiment. 
 
Chemical Screening 
Initially, transcriptional assays were used to measure activation of both cPXR and 
hPXR by the prototypical human PXR ligands RIF and DEX at a concentration of 10-6 
M, comparing two separate reporter constructs in assessing for PXRE function.  In 
addition to the pGL4.24-6xPXRE reporter construct, a commercially available 
MMTV/luc2/pGL4 reporter vector (Promega) was tested as a reporter plasmid (i.e. for 
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PXRE function), as it is known to contain various nuclear receptor response elements 
in the promoter region.  
The pGL4.24-6xPXRE construct was subsequently used as the reporter construct 
in transcriptional assays to establish concentration-response curves for the receptor 
agonists RIF and CTZ in the concentration ranges of 10-11 M to 10-5 M for both cPXR 
and hPXR.  Subsequently, pharmaceuticals of different therapeutic classes were 
screened for their ability to activate hPXR and cPXR.  These were: the non-steroidal 
anti-inflammatory drugs (NSAIDs) diclofenac (DIC), ibuprofen (IBU) and ketoprofen 
(KTP); the fibrates clofibric acid (CFA) and gemfibrozil (GEM); the β–blockers 
propranolol (PRP) and atenolol (ATN); the (anti)oestrogens 17α-ethinyloestradiol 
(EE2) and tamoxifen (TAM); and the azole antifungal drugs ketoconazole (KTZ) and 
miconazole (MCZ).  Propiconazole (PCZ), an agricultural azole antifungal was also 
included in the analyses.  For all compounds, dose-response curves were 
established in the concentration ranges of 10-11 M to 10-5 M, for both cPXR and 
hPXR.   
All compounds (obtained from Sigma-Aldrich) were dissolved and diluted in DMSO 
and added to the medium.  The final solvent concentration in the transactivation 
assays was 0.1% DMSO and control wells were dosed with 0.1% DMSO only. 
 
Data Analysis 
Data are presented throughout as mean ± standard error of the mean (SEM).  All 
transfections were performed in triplicate and repeated three times on cells with 
different passage numbers.  Concentration–response data using a four-parametric 
curve fitting and EC50 (for agonists) were analysed using GraphPad Prism (Graph 
Pad Software Inc.).  Chemical responses were normalised against their relevant 
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respective controls.   Statistical analyses were carried out using SigmaPlot® software 
(Systat Software, Inc.) and p<0.05 was considered statistically significant.  
 
 
Results 
Cloning of full-length cPXR and sequence analysis 
Using 5’- and 3’-RACE PCR, the full-length cDNA sequence of cPXR was isolated 
from carp liver.  The fragment obtained was composed of 1696 nucleotides, 
containing 262 and 99 base pairs of the 5’- and 3’-untranslated regions, respectively.  
The open reading frame of the cPXR nucleotide sequence predicts a protein of 444 
amino acid residues. The full-length sequence obtained for cPXR has been 
deposited in the GenBank database (accession # KX241860).  Sequence analyses 
showed that cPXR has a highly conserved DNA binding domain (DBD) consisting of 
two C4-type zinc fingers and including a P-box motif (CEGCKG; a sequence 
essential for DNA-binding specificity) and a conserved ligand-binding domain (LBD) 
including the AF-2 motif (PLxxEx), essential for co-regulator interaction during ligand 
binding of transcription factors.  BLASTp analysis (Altschul et al., 1997) confirmed 
sequence identity and revealed a high homology between the amino sequence of the 
DBD of the cPXR with the zebrafish PXR (98%) and human PXR (74% ) (Figure 2).  
The overall amino acid identity of cPXR with other PXR sequences was between 46 
– 78 %.  In a phylogenetic analysis, the teleost PXR forms a distinct clade with the 
cPXR most similar to PXR of zebrafish (Figure 3). 
 
Comparison of reporter plasmids 
Initially, both cPXR and hPXR reporter assays were investigated using two 
different reporter vectors, namely the pGL4.24-6xPXRE  construct and the 
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commercial MMTV/luc2/pGL4 plasmid, to test for responses to PXR activation (i.e. 
for a functional PXRE) (Figure 4).  The test system transfected with pGL4.24-
6xPXRE showed significant activation of the hPXR in those cells exposed to 1 µM 
RIF compared with the control.  cPXR activity also appeared to be higher in cells 
exposed to 1 µM RIF compared with control cells, although this was not supported 
statistically (p>0.05).  The test system transfected with the MMTV/luc2/pGL4 plasmid 
in contrast showed no significant treatment-related activation with respect to either 
hPXR or cPXR.  pGL4.24-6xPXRE was used as the reporter plasmid in all 
subsequent transactivation concentration-response assays. 
 
Responses of PXRs to known PXR agonists 
Concentration-dependent transactivation of hPXR was observed after exposure to 
concentrations between 10 µM and 10 pM RIF (Figure 5).  RIF activated hPXR with a 
maximal effect (Emax) 6.4 times that of the control and an EC50 of 2.04 µM.  cPXR 
was not activated by RIF. 
CTZ activated both the hPXR and cPXR, but with different potencies.  For hPXR, 
the EC50 was 0.88 µM with an Emax of 4.8, and for cPXR, the EC50 was 0.024 µM with 
an Emax of 10.9. 
 
Activation of cPXR and hPXR by pharmaceuticals and fungicides 
All three NSAIDs (DIC, IBU and KTP), both fibrates (CFA and GEM) and the β-
blocker (ATN) did not induce transactivation of either cPXR or hPXR at any of the 
concentrations tested (Figure 6A-F).  Propranolol activated hPXR (EC50 = 44 nM), but 
had no effect on cPXR (Figure 6G). EE2 appeared to induce luciferase activity in 
both cPXR and hPXR, but did so only at high (10 μM) concentrations (Figure 6H).  
TAM had no effect on cPXR and only induced transactivation of hPXR at 10 µM 
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(Figure 6I).  This treatment level, however, would likely have been approaching a 
toxicity level; 100 µM TAM was toxic to COS-7 cells in both, cPXR and hPXR assays 
as established by an inhibited cell growth.  The azole antifungals MCZ and PCZ 
induced transactivational activity of both, cPXR and hPXR.  For cPXR, the estimated 
EC50s were 0.315 µM MCZ and 0.213 µM PCZ.  For hPXR, higher concentrations of 
MCZ and PCZ were required to induce transactivation of cPXR and hPXA and full 
dose-response curves were not obtained (Figure 6K, L).  KTZ had no effect on cPXR 
or hPXR transactivation (Figure 6J). 
 
 
Discussion 
In this study, we cloned a full-length PXR sequence from the common carp which, 
based on sequence analyses, was identified as an orthologue of human and mouse 
PXR.  The percent identities of the cPXR DBD and LBD reported here are in 
agreement with those published for other fish species, including the zebrafish, 
another cyprinid species (Bainy et al., 2013; Krasowski et al., 2005; Milnes et al., 
2008).  Of all of the nuclear receptors, vertebrate PXR sequences show the greatest 
sequence and functional differences between species. The amino acid sequence of 
the PXR LBD shows an unusually high sequence divergence between different 
orthologues (Handschin and Meyer, 2003; Iyer et al., 2006).  It is speculated that the 
varying degrees of sequence conservation of the vertebrate PXR LBD and resulting 
broad ligand specificity of PXR might reflect variation in exogenous PXR ligands as 
well as species physiology (Krasowski et al., 2011). 
Here, using the pGL4.24-6xPXRE construct as reporter plasmid, the hPXR was 
activated by RIF and by CTZ, both well-established PXR agonists in humans.  The 
hPXR was activated by RIF with an EC50 of 2.04 µM, and Emax of 6.4 µM, and CTZ 
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with an EC50 of 0.88 µM, both of which are comparable to those previously reported 
in humans (Bertilsson et al., 1998; Blumberg et al., 1998; Lemaire et al., 2004; Milnes 
et al., 2008; Moore et al., 2000; Sinz et al., 2006; Svecova et al., 2008).  DEX, 
conversely, failed to activate the hPXR.  Although DEX is a potent agonist of the 
rodent PXR, it is only a weak agonist of hPXR (Kliewer et al., 2002) and the response 
seen here is comparable with that reported previously for the hPXR following 
treatment with  2 µM DEX (Luo et al., 2002).  In summary, the activation of the hPXR 
in the transfection assay, established for RIF, CTZ and DEX, were consistent with 
previous reports on the responsiveness of the hPXR to these compounds. 
In this study, cPXR did not respond to RIF, supporting findings for the zebrafish 
PXR (Moore et al., 2000).  Contrasting with these cyprinid fish RIF (50 µM) has been 
shown to activate PXR from the pufferfish (Takifugu rubripes) (Milnes et al., 2008).  
Interestingly, RIF also shows species differences in mammals as a PXR ligand.  For 
example, RIF activates PXR strongly in humans and rabbits, but does so only 
relatively weakly in rodents (Kliewer et al., 2002).  This difference is thought to be 
due to sequence differences in the LBD.  This may also be the case for fish; carp and 
zebrafish PXR share high sequence similarity (79%) whereas Fugu Sp PXR shares 
only 52% and 51% sequence homology with carp and zebrafish PXR, respectively.  
In mammals, this species-specificity for PXR ligand activation parallels responses (or 
lack thereof) in expression of cyp3a to the same ligands (Kliewer et al., 2002; Luo et 
al., 2002); cyp3a is transcriptionally regulated directly by PXR.  The lack of a 
response of the cPXR to RIF seen here is, however,  contrasts with  previous gene 
expression profiles for cyp3a (Corcoran et al., 2012).  In carp, we have shown 
previously that cyp3 and a number of genes associated with the PXR in mammals 
were up-regulated in a concentration-dependent manner by RIF, and in some cases 
at concentrations as low as 0.1 µM.  Furthermore, this induction was inhibited by co-
15 
 
exposure to ketoconazole, which is known to antagonise the interaction of RIF with 
the PXR.  In other fish species too, RIF has been shown to induce CYP3A enzyme 
activity in vitro.  Examples include in  FHM cell line (Christen et al., 2010), and in 
primary hepatocytes from grass carp and largemouth bass, albeit at relatively high 
exposure levels (highest net increase in aminopyrine N-demethylase activity was 
reached at 52.43 and 45.28 µM, respectively (Li et al., 2008)).  The lack of response 
of the cPXR to RIF in the present study is, therefore, somewhat unexpected, and 
may suggest that the observed up-regulation of teleost biotransformation genes and 
enzymes by RIF may involve non-PXR mediated mechanism(s). 
In mammals, there is evidence for considerable crosstalk between PXR and other 
nuclear receptors and transcription factors, including farnesoid X receptor (FXR), 
glucocorticoid receptor (GR) and vitamin D receptor (VDR), in the regulation of 
biotransformation genes (Pascussi et al., 2008).  This sort of interaction may account 
for the discrepancy between the responses of teleost CYP3A at the gene and 
enzyme level previously observed and the PXR activation profile presented here.  
For example, in rodents GR has also been shown to regulate expression of cyp3a, 
possibly explaining  the inconsistencies between induction of cyp3a expression 
against a weak activation of the PXR by DEX (a GR ligand) (Quattrochi and Guzelian, 
2001).  
It is also the case that PXR activation may require various co-factors, co-
repressors, transcription factors and/or complexes that interact with the PXR or the 
response element (Quattrochi and Guzelian, 2001), as is common for other nuclear 
receptors.  Whether all of the required factors for the activation of cPXR by RIF are 
present in the transfection assay cell systems is not known.  
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The cPXR was more sensitive to CTZ compared with the human isoform and this 
is consistent with findings in other fish species where PXR has been shown to be 
highly responsive to CTZ.  Examples include the zebrafish PXR  shown to be up 
regulated in transfection assays by 8-fold (above controls) for exposure 
concentrations between 0.5 and 50 µM (Bainy et al., 2013; Milnes et al., 2008; Moore 
et al., 2000) and in the FHM PXR by up to 35-times for exposure to 50 µM CTZ 
(Milnes et al., 2008). 
CTZ concentrations in effluent and surface waters are generally in the low ng l-1 
range, but in sewage effluent have been reported at concentrations up to 1.8 µg l-1  
(Peng et al., 2012) which are approaching the lowest effect concentration reported 
here.  Moreover, CTZ has been shown to bio-concentrate in fish (Corcoran et al., 
2014), with a plasma bioconcentration factor (BCFplasma) of between 20 and 45, 
leading to the possibility of higher target tissue concentrations of this compound in 
exposed fish. 
The PXR activation by CTZ demonstrated in fish does not always parallel 
expression of some PXR-associated genes, in particular cyp3a, either in vivo or in 
vitro (Bresolin et al., 2005; Corcoran et al., 2012; Crago and Klaper, 2011; Wassmur 
et al., 2013).  We have though previously demonstrated up-regulation in the 
expression of a number of biotransformation genes, (including cyp3a) in carp 
exposed in vivo for 10 days to measured water concentrations of 17 µg CTZ l-1 
(Corcoran et al., 2014).  Some inconsistencies between PXR activation and gene 
responses in the different carp studies, however, are still apparent.  In this study 
cPXR was activated in vitro by CTZ at concentrations 100 times lower than those 
shown to induce expression of biotransformation genes in vivo.  It is possible that a 
certain threshold level of PXR activation is required to subsequently induce activation 
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of downstream gene targets.  Equally, it is possible that the PXRE construct does not 
reflect the sensitivity of carp PXRE motifs in target genes in vivo.  An alternative 
explanation is that activation of the teleost PXR does not lead to induction of 
biotransformation genes, as is known to occur in mammals. 
Globally, pharmaceuticals have been detected in surface waters and wastewater 
treatment work effluents (reviewed in Aus der Beek et al., 2016) and are of concern 
to receiving biota due to their biological specificity and potency (reviewed in Corcoran 
et al., 2010).  In mammals, PXR is known to play a significant role in regulating drug 
biotransformation (Liddle and Goodwin, 2002) whereas in fish, very limited 
information is available on the involvement of PXR in drug biotransformation.  
Various pharmaceuticals have been described as CYP3A inducers in human through 
their ability to activate PXR (Sinz et al., 2006).  Previous studies have also indicated 
a potential involvement of PXR in regulating selected genes involved in drug 
metabolism in fish (Corcoran et al., 2012).  Five out of 11 pharmaceuticals we tested 
(PRP, EE2, TAM, KTZ and MCZ) were found to activate hPXR, albeit only partially 
and some were very weak in their capacity to do so.  cPXR, on the other hand, was 
activated by EE2 and MCZ.  The lack of hPXR transactivation by IBU is consistent 
with previous findings, but for DIC contrasts with that reported previously for the 
hPXR (Creusot et al., 2010; Sinz et al., 2006).  Contrasting with our findings here that 
IBU and CFA had no effect on cPXR transactivation, previously using carp 
hepatocyte cultures, we found that these compounds induce an up-regulation in 
expression of the biotransformation genes cyp2k, cyp3a, gsta, gstp, mdr1 and mrp2 
(Corcoran et al., 2012) and for CFA this was mirrored for an in vivo exposure in carp 
(Corcoran et al., 2015).  The lack of hPXR activation by the fibrates (GEM and CFA) 
is consistent with a previous finding for hPXR in transactivation assays (Sinz et al., 
2006).  For some compounds, in particular CTZ and PRP, a higher variability was 
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observed in response to the higher agonist concentrations tested and onset of 
cytotoxicity or solubility are both possible explanations for this variability.  Cytotoxicity 
is an unlikely factor as the cells did not show any signs of morphological changes.  In 
terms of solubility, of the compounds yielding variable responses, only the highest 
CTZ concentration was bordering water solubility limits.  The reason for high 
variability for some a few of the data points across multiple experiments appears to 
relate to the variation in the technical replicates, which we are unable to account for. 
The β-blocker PRP activated the hPXR, but neither of the β-blockers tested 
activated the cPXR transactivation assay.  For both β-blockers tested, no detectable 
transactivation of hPXR has been demonstrated previously (Sinz et al., 2006).  We 
have though shown an up-regulation of cyp2k, cyp3a, mdr1 and mrp2 gene 
expression in carp primary hepatocytes in response to PRP exposure previously 
(Corcoran et al., 2012). 
EE2 induced transactivation of both cPXR and hPXR albeit only at the highest 
exposure concentration tested (10 µM), whereas TAM induced transactivation of 
hPXR only, at 1 µM and did so only weakly.  Transactivational activity at the hPXR 
has been shown previously for both drugs (Sinz et al., 2006). 
The azole fungicides were the only class of compounds showing consistent effects 
between both hPXR and cPXR.  In mammals, azoles are known to be both inhibitors 
and inducers of specific hepatic biotransformation systems, the effects being 
mediated through PXR (Hester et al., 2012; Huang et al., 2007; Sun et al., 2005; 
Wang et al., 2007).  Both MCZ and PCZ induced transactivation of cPXR and hPXR 
and they were more potent in the cPXR.  In vivo studies have shown PCZ induces 
CYP2B and CYP3A isoforms in rat and mouse liver as well as hepatic cyp3a gene 
expression in fathead minnow (Skolness et al., 2013; Sun et al., 2005).  Collectively, 
these findings indicate that PCZ is a potent activator of PXR and suggests a common 
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pathway between fish and mammals.  In line with our findings, MCZ has been 
identified in humans as potent PXR ligand, also inducing CYP3A4 (Dvorak, 2011; 
Svecova et al., 2008).  To the best of our knowledge, no other data are available on 
the effects of MCZ on fish.  In our in vitro assays, KTZ did not induce transactivation 
of cPXR or hPXR.  In carp hepatocytes, co-exposure to RIF and KTZ resulted in an 
inhibition of the gene expression responses of cyp2k and cyp3a, and KTZ alone had 
an effect on cyp2k, but no effect on cyp3a (Corcoran et al., 2012).  In rainbow trout 
and killifish, KTZ is known to induce CYP3A protein expression, but inhibit its 
catalytic activity in vivo and in vitro (Hegelund et al., 2004). 
Overall, our data show species differences in the potency of xenobiotics to 
transactivate PXR in vitro, however, in all cases cPXR transactivation occurred at 
concentrations exceeding those with environmental relevance.  As an example, the 
EC50s determined for the most potent cPXR agonists were 0.315 µM MCZ and 
0.213 µM PCZ, whereas measured average environmental concentrations are 
generally in pico- to nanomolar ranges (e.g. 0.019 nM MCZ and 0.85 nM PCZ) 
(Battaglin et al., 2011; Roberts and Bersuder, 2006).  Similarly for EE2, low 
micromolar concentrations were required to induce a weak transactivation of cPXR 
and the average concentration of EE2 in surface waters globally is sub-nanomolar 
(Aus der Beek et al., 2016).  We are not excluding the possibility that environmental 
exposure to these compounds does not pose any possible risk for adverse effects, 
but the likelihood is low for any individual compound.  There are, however, complex 
mixtures of PXR receptor agonists in the aquatic environment and when in 
combination, compounds with low individual efficacy can activate hPXR in a 
synergistic manner (Delfosse et al., 2015). 
There are considerable challenges when comparing data sets for PXR activation 
across the different published studies even for the reporter gene assay systems 
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alone.  The reasons for this include that a variety of different cell lines have been 
used, and that some transactivation assays employ a reporter construct consisting 
only of the PXR LBD rather than the full PXR sequence.  To illustrate the differences 
in transactivation assays that can occur for sequence inclusions of different sizes, 
exposure to CTZ was shown to result in a considerably lower (90% lower) activation 
of a zebrafish full-length PXR compared with a zebrafish PXR-LBD construct (Bainy 
et al., 2013).  This serves to emphasise that while reporter assays offer excellent in 
vitro tools to screen for PXR activation, functional studies either employing 
hepatocyte cultures or in vivo experimental approaches are needed for the validation 
of any effects seen. 
Overall, the data presented suggest that the reporter gene assay developed for 
activation of cPXR is a sensitive and reproducible model system for characterising 
the ligand activation profile of the PXR in carp.  This assay can be applied effectively 
for screening chemicals, including pharmaceutical, and/or environmental samples for 
PXR activation, for use in prioritising risk assessments.  Application of the assay has 
identified possible differences between the PXR associated xenobiotic-metabolising 
pathway in mammals compared with in fish. This being the case fish (carp) may be 
poor models for studying chemical activation of human PXR function.  Our findings 
further indicate that fish may have different metabolic pathways for detoxification of 
some of the key chemicals of environmental concern with possible implications for 
hazard identification and risk assessment. 
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Figure captions 
Figure 1.  Sequence of the 6xPXRE reporter construct. Nucleotides shown in green 
are PXRE sequences. Capital letters mark the conserved motifs.  The boxed section 
is a DR4 based on that published by Xie et al. (2000).  This sequence was inserted 
into the pGL4.24 vector using KpnI and HindIII restriction sites (underlined) to create 
the PXRE reporter vector.  Arrows indicate the direction of the nuclear response 
element repeat motif. 
 
Figure 2.  cPXR amino acid sequence aligned with PXR sequences of other animal 
species. The highly conserved DBD (blue outline) consists of two C4-type zinc 
fingers and includes a P-box motif (red outline). The conserved LBD (green outline) 
includes the AF-2 motif (purple outline). Accession numbers of sequences used for 
alignment: AAH17304 (H. sapiens); NP_443212 (R. norvegicus); NP_035066 (M. 
musculus); NP_001092087 (D. rerio). 
 
Figure 3.  Evolutionary relationships of PXR.  The neighbor-joining phylogenetic tree 
was constructed based on full length amino acid sequences. The scale bar 
represents 0.05 substitutions per site. 
 
Figure 4.  Activation of cPXR and hPXR by rifampicin (RIF) and dexamethasone 
(DEX) mediated by two different luciferase reporter vectors.  An asterisk denotes the 
treatment is significantly different from the corresponding DMSO control group 
(p<0.05). 
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Figure 5.  Concentration-response curves for carp (solid line) and human (dashed 
line) PXR activation on exposure to (A) rifampicin and (B) clotrimazole for 44 hours at 
concentration between 10 µM and 10 pM (10-5 and 10-11 M). Data are presented as x-
fold activation relative to DMSO control 
 
Figure 6.  Concentration–response profiles of cPXR and hPXR exposure to: the 
NSAIDs diclofenac (A), ibuprofen (B) and ketoprofen (C); the fibrates clofibric acid 
(D) and gemfibrozil (E); the β-blockers atenolol (F) and propranolol (G); the (anti-
)oestrogens 17α-ethinyloestradiol (H) and tamoxifen (I); and the antifungals 
ketoconazole (J), miconazole (H) and propiconazole (L).  Results are expressed as 
mean change normalised against their relevant respective controls ± SEM.  Dose-
response-curves were fitted by non-linear regression. 
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Highlights 
 Establishment of a reporter gene assay for carp PXR 
 PXR-transactivation differs with agonists and species 
 Implications of species-differences in PXR for risk assessment 
 Fish might not be good models for studying potential chemical activation of 
human PXR 
 
